semaglutide effect on heart VisualAbstract: Improves Outcomes in Patients with Obesity-Related Failure and Type 2 Diabetes Long-Term SELECT Trial: Semaglutide Cuts

The SURMOUNT-2 trial (2023) focused specifically on patients with type 2 diabetes and obesity, demonstrating average weight loss of 14.7% at the 15 mg dose, a substantial improvement over prior GLP-1 monotherapy results in this population

What is the average weight loss with Saxenda

For the most accurate and up-to-date information on whether Wegovy is covered, contact your insurance company directly

Food and Drug Administration FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize FDA Drug Safety and Availability Guidance 2024 6 Rubino D, Abrahamsson N, Davies M, et al

Incretins are gut-derived hormones, members of the glucagon superfamily